Physician profile
Walter E Donnelly
NPI 1730142407
$9,362.93
in general payments reported to CMS, 2019-2025
59 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,710 · 2020: $1,379 · 2021: $1,423 · 2022: $930 · 2023: $1,556 · 2024: $1,252 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,920.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,031.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $749.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $723.52 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $644.01 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Sanofi-Aventis U.S. LLC | $639.67 | 2019-2025 | |
| Amgen INC. | $432.60 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $430.30 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $426.26 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $349.64 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $305.63 | 2020-2025 | Austedo Xr, Austedo, Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.26 | 2019-2024 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $266.16 | 2019-2025 | |
| Amarin Pharma, INC. | $229.26 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $228.14 | 2020-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Bayer Healthcare Pharmaceuticals INC. | $202.90 | 2021-2024 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.02 | 2019-2025 | Xifaxan, Cycloset |
| Corcept Therapeutics | $178.22 | 2020-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $164.65 | 2020-2024 | Gvoke Hypopen, Recorlev |
| Astellas Pharma US INC | $159.74 | 2019-2024 | Myrbetriq, Veozah |
| Exact Sciences Corporation | $153.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $96.97 | 2023-2024 | Rexulti, Nuedexta |
| Esperion Therapeutics, INC. | $91.27 | 2020-2023 | Nexletol |
| Insulet Corporation | $89.87 | 2019-2025 | Omnipod |
| Cranial Technologies, INC | $89.23 | 2019-2021 | |
| Lifescan, INC. | $81.55 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $77.08 | 2023-2024 | Gemtesa |
| Eisai INC. | $73.76 | 2020-2021 | |
| Beta Bionics, INC. | $69.08 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Mannkind Corporation | $67.52 | 2022-2023 | Afrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.73 | 2025 | Caplyta |
| Allergan, INC. | $60.33 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $58.55 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $57.34 | 2019-2025 | Nuzyra, Xhance |
| Takeda Pharmaceuticals U.S.A., INC. | $43.86 | 2021-2022 | |
| Abbott Laboratories | $43.63 | 2019-2023 | Infinity |
| Ironshore Pharmaceuticals INC. | $43.00 | 2019 | |
| Horizon Therapeutics Plc | $39.59 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $36.40 | 2021 | |
| Medtronic, INC. | $33.89 | 2022 | |
| Dexcom, INC. | $33.01 | 2021-2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $27.09 | 2019 | |
| Valeritas, INC. | $25.43 | 2019 | |
| Teleflex LLC | $24.18 | 2025 | Urolift |
| Sanofi Pasteur INC. | $22.56 | 2023 | |
| Acadia Pharmaceuticals INC | $22.45 | 2025 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $20.32 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $18.65 | 2024 | |
| Grifols USA, LLC | $16.00 | 2023 | Prolastin-C Liquid |
| Alexion Pharmaceuticals, INC. | $15.22 | 2023 | Strensiq |
| Avanir Pharmaceuticals, INC. | $14.79 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.30 | 2024 | Eliquis |
| Boston Scientific Corporation | $14.29 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.83 | 2023 | Quviviq |
| Seqirus USA INC | $12.82 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Ucb, INC. | $12.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.06 | 2021 | |
| Sun Pharmaceutical Industries INC. | $11.23 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $11.15 | 2019 | |
| Cequr Corporation | $5.01 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Donnelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.